BR112023023391A2 - Inibidor de diminuição de esteroide de receptor de interferon tipo 1 em pacientes com lúpus eritematoso sistêmico - Google Patents

Inibidor de diminuição de esteroide de receptor de interferon tipo 1 em pacientes com lúpus eritematoso sistêmico

Info

Publication number
BR112023023391A2
BR112023023391A2 BR112023023391A BR112023023391A BR112023023391A2 BR 112023023391 A2 BR112023023391 A2 BR 112023023391A2 BR 112023023391 A BR112023023391 A BR 112023023391A BR 112023023391 A BR112023023391 A BR 112023023391A BR 112023023391 A2 BR112023023391 A2 BR 112023023391A2
Authority
BR
Brazil
Prior art keywords
lupus erythematosus
systemic lupus
patients
steroid
receptor type
Prior art date
Application number
BR112023023391A
Other languages
English (en)
Inventor
Gabriel Abreu
Rajendra Tummala
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of BR112023023391A2 publication Critical patent/BR112023023391A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Abstract

nibidor de diminuição de esteroide de receptor de interferon tipo 1 em pacientes com lúpus eritematoso sistêmico. a presente invenção refere-se a métodos e composições para o tratamento de lúpus eritematoso sistêmico (sle).
BR112023023391A 2021-05-12 2022-05-11 Inibidor de diminuição de esteroide de receptor de interferon tipo 1 em pacientes com lúpus eritematoso sistêmico BR112023023391A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163187485P 2021-05-12 2021-05-12
US202163230113P 2021-08-06 2021-08-06
PCT/EP2022/062770 WO2022238479A1 (en) 2021-05-12 2022-05-11 Inhibitor of type 1 interferon receptor steroid sparing in systemic lupus erythematosus patients

Publications (1)

Publication Number Publication Date
BR112023023391A2 true BR112023023391A2 (pt) 2024-01-23

Family

ID=82019468

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112023023391A BR112023023391A2 (pt) 2021-05-12 2022-05-11 Inibidor de diminuição de esteroide de receptor de interferon tipo 1 em pacientes com lúpus eritematoso sistêmico

Country Status (9)

Country Link
EP (1) EP4337696A1 (pt)
JP (1) JP2024516886A (pt)
KR (1) KR20240006549A (pt)
AU (1) AU2022274306A1 (pt)
BR (1) BR112023023391A2 (pt)
CA (1) CA3219401A1 (pt)
IL (1) IL308128A (pt)
TW (1) TW202313103A (pt)
WO (1) WO2022238479A1 (pt)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2662390T3 (da) 2004-06-21 2017-11-06 Squibb & Sons Llc Interferon alpha receptor 1-antistoffer og anvendelse heraf
JP5608100B2 (ja) 2008-02-08 2014-10-15 メディミューン，エルエルシー 低下したＦｃリガンド親和性を有する抗ＩＦＮＡＲ１抗体
PT2473636T (pt) 2009-09-03 2017-02-06 Medimmune Llc Diagnóstico de interferão de tipo-1
ES2818229T3 (es) * 2015-08-19 2021-04-09 Astrazeneca Ab Formulación anti-IFNAR1 estable
CN106243226B (zh) 2016-08-05 2019-02-12 北京智仁美博生物科技有限公司 抗人ifnar1的抗体及其用途
CN113278070B (zh) 2021-04-25 2022-06-14 福州迈新生物技术开发有限公司 抗ck17蛋白单克隆抗体及其细胞株、制备方法和应用

Also Published As

Publication number Publication date
KR20240006549A (ko) 2024-01-15
TW202313103A (zh) 2023-04-01
CA3219401A1 (en) 2022-11-17
AU2022274306A1 (en) 2023-11-23
EP4337696A1 (en) 2024-03-20
JP2024516886A (ja) 2024-04-17
AU2022274306A9 (en) 2023-11-30
IL308128A (en) 2023-12-01
WO2022238479A1 (en) 2022-11-17

Similar Documents

Publication Publication Date Title
BR112015027288A8 (pt) uso de uma dose de imunossupressor, composição de nanocarreadores sintéticos tolerogênicos e kit
BR112015029987A2 (pt) beta-caseína a2 e a prevenção de inflamação do intestino
BR112017011644A2 (pt) métodos e composições de ativação da ligase parkina
BR112015027757A2 (pt) elastômeros parcialmente fluorados e métodos para a produção e uso dos mesmos
BR112015025321A2 (pt) dispositivo suplementar para um dispositivo de injeção operável manualmente
BR112014009528A8 (pt) métodos e composições para tratar eritropoiese ineficaz
BR112022007677A2 (pt) L-asparaginase recombinante
BR112017009440A2 (pt) uso de composições que modulam a estrutura de cromatina quanto à doença do enxerto versus hospedeiro (gvhd)
BR112016024022A2 (pt) composição de silicone curável
BR112022011902A2 (pt) Terapias de combinação
BR112017024180A8 (pt) Aparelho de alimentação de prendedores
BR112017027246A2 (pt) marcador de indução de degradação de proteína e uso do mesmo
BR112014000542A2 (pt) composições de peroxidase eosinofílica e métodos de uso das mesmas
BR112019000989A2 (pt) método para tratar sulfeto de hidrogênio em uma corrente, sequestrante, composição, e, uso de uma composição
CY1115775T1 (el) Συνθεση ψυκτικου μεσου
BR112018067851A2 (pt) composições e métodos para o tratamento de artrite reumatoide
CO2021002637A2 (es) Arni variante frente a alfa-sinucleína
CO2022000270A2 (es) Inhibidores de enzimas
BRPI0512642A (pt) aparelho e método de proteção contra corrosão
BR112023023391A2 (pt) Inibidor de diminuição de esteroide de receptor de interferon tipo 1 em pacientes com lúpus eritematoso sistêmico
BR112013005887A2 (pt) compostos de sacarídeo substituído e composições dentais
BR112015032339A8 (pt) Composição resistente à água
BR112017011375A2 (pt) fio de aço de alta resistência à tensão
BR112017012994A2 (pt) chapa de aço elétrica
BR112019000635A2 (pt) inibidor de receptor 2 do tipo toll (tlr2) e seu uso, anticorpo, composição e método para tratar uma afecção inflamatória